Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects

Alexandra AI Abel, Andrew L Clark Department of Academic Cardiology, Castle Hill Hospital, Kingston Upon Hull, UKCorrespondence: Alexandra AI AbelDepartment of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UKEmail alexandra.abel@hyms.ac.ukAbstract: Heart failur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abel AAI, Clark AL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	heart failure hefref myocardial infarction Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9d2212fca2bb49598182515b0b72ab76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9d2212fca2bb49598182515b0b72ab76
record_format	dspace
spelling	oai:doaj.org-article:9d2212fca2bb49598182515b0b72ab762021-11-09T18:40:34ZLong-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects1178-7074https://doaj.org/article/9d2212fca2bb49598182515b0b72ab762021-11-01T00:00:00Zhttps://www.dovepress.com/long-term-pharmacological-management-of-reduced-ejection-fraction-foll-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Alexandra AI Abel, Andrew L Clark Department of Academic Cardiology, Castle Hill Hospital, Kingston Upon Hull, UKCorrespondence: Alexandra AI AbelDepartment of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UKEmail alexandra.abel@hyms.ac.ukAbstract: Heart failure (HF) with reduced ejection fraction is common following acute myocardial infarction (MI), and active medical management can have a profound impact on prognosis. Reviewing relevant clinical trials, we focus on the pharmacological management of left ventricular systolic dysfunction (LVSD) following an acute MI, although there is overlap with the pharmacological management of chronic HF due to reduced ejection fraction. Angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists are the mainstay of medical management in patients with LVSD post MI; there may also be a role for anticoagulation. Sacubitril-valsartan (angiotensin receptor neprilysin inhibitor) has not yet been shown to be superior to an ACE inhibitor in reducing cardiovascular mortality and HF events in patients with LVSD post MI. Large randomised trials evaluating sodium glucose transporter 2 (SGLT-2) inhibitors in LVSD post MI are ongoing.Keywords: heart failure, HeFREF, myocardial infarctionAbel AAIClark ALDove Medical Pressarticleheart failurehefrefmyocardial infarctionMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 7797-7805 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	heart failure hefref myocardial infarction Medicine (General) R5-920
spellingShingle	heart failure hefref myocardial infarction Medicine (General) R5-920 Abel AAI Clark AL Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
description	Alexandra AI Abel, Andrew L Clark Department of Academic Cardiology, Castle Hill Hospital, Kingston Upon Hull, UKCorrespondence: Alexandra AI AbelDepartment of Academic Cardiology, Castle Hill Hospital, Cottingham, Kingston-Upon-Hull, HU16 5JQ, UKEmail alexandra.abel@hyms.ac.ukAbstract: Heart failure (HF) with reduced ejection fraction is common following acute myocardial infarction (MI), and active medical management can have a profound impact on prognosis. Reviewing relevant clinical trials, we focus on the pharmacological management of left ventricular systolic dysfunction (LVSD) following an acute MI, although there is overlap with the pharmacological management of chronic HF due to reduced ejection fraction. Angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists are the mainstay of medical management in patients with LVSD post MI; there may also be a role for anticoagulation. Sacubitril-valsartan (angiotensin receptor neprilysin inhibitor) has not yet been shown to be superior to an ACE inhibitor in reducing cardiovascular mortality and HF events in patients with LVSD post MI. Large randomised trials evaluating sodium glucose transporter 2 (SGLT-2) inhibitors in LVSD post MI are ongoing.Keywords: heart failure, HeFREF, myocardial infarction
format	article
author	Abel AAI Clark AL
author_facet	Abel AAI Clark AL
author_sort	Abel AAI
title	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
title_short	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
title_full	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
title_fullStr	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
title_full_unstemmed	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects
title_sort	long-term pharmacological management of reduced ejection fraction following acute myocardial infarction: current status and future prospects
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/9d2212fca2bb49598182515b0b72ab76
work_keys_str_mv	AT abelaai longtermpharmacologicalmanagementofreducedejectionfractionfollowingacutemyocardialinfarctioncurrentstatusandfutureprospects AT clarkal longtermpharmacologicalmanagementofreducedejectionfractionfollowingacutemyocardialinfarctioncurrentstatusandfutureprospects
_version_	1718440867004416000

Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects

Ejemplares similares